SAT0037 Serum 14-3-3Eta Predicts the Risk of RA Development and Its Higher Titres Are Associated with Higher Risk

Autor: Maarten Boers, Anthony Marotta, Walter P. Maksymowych, D. van Schaardenburg, M. van Beers-Tas
Rok vydání: 2014
Předmět:
Zdroj: Annals of the Rheumatic Diseases. 73:602.1-602
ISSN: 1468-2060
0003-4967
DOI: 10.1136/annrheumdis-2014-eular.3326
Popis: Background 14-3-3eta (η) is a mechanistic biomarker that is useful in RA diagnosis. We have previously reported that its plasma expression precedes and independently predicts RA development in arthralgia subjects. 14-3-3η titres further improve the predictive value of variables such as ACPA, number of painful joints and alcohol non-use, which are independently associated with RA development. Objectives To determine whether higher 14-3-3η serum cut-off informs a higher likelihood of RA development in arthralgia patients. Methods 14-3-3η plasma levels were measured in 148 consecutive arthralgia patients of whom 44 (30%) developed RA [median time to RA, 14.5 months, range (1-68)] and 104 did not. Entry into the cohort was based on the absence of clinical arthritis at baseline but a positive ACPA and/or IgM-RF status and a history of arthralgia. 14-3-3η positivity was defined by the diagnostic cut-off of ≥0.19 ng/ml and a second cut-off of ≥0.80 ng/ml was set at the 75th percentile serum level of the group that did not develop RA. Fisher exact test and stepwise multivariate analyses were performed to determine 14-3-3η9s association with other clinical/serological markers for RA development risk. Variables included in the model were ACPA positivity, alcohol non-use, VAS pain, morning stiffness and number of total painful joints. Results 14-3-3η median plasma levels were significantly higher in the group that developed RA [0.9 (0.2-6.9) vs 0.3 (0.2-0.8) ng/ml, p Conclusions Plasma 14-3-3η titres are independently associated with RA development and levels ≥0.80 ng/ml are associated with a higher likelihood of developing RA. These findings are consistent with the mechanistic understanding of 14-3-3η9s deleterious role in the pathophysiology of RA. Disclosure of Interest D. van Schaardenburg: None declared, W. Maksymowych Consultant for: Augurex Life Sciences Corp, M. Boers: None declared, M. van Beers-Tas: None declared, A. Marotta Employee of: Augurex Life Sciences Corp DOI 10.1136/annrheumdis-2014-eular.3326
Databáze: OpenAIRE
Externí odkaz: